Role of Antioxidants in Modulating BDNF Signaling and Oxidative Stress in Glioblastoma: Current Evidence and Therapeutic Perspectives
- 1Department of Life Sciences, Yeungnam University, Gyeongsan 38541, Republic of Korea
Abstract
Glioblastoma (GBM) remains one of the most aggressive and lethal brain tumors, with limited treatment success despite standard multimodal therapy. Oxidative stress and dysregulated brain-derived neurotrophic factor (BDNF) signaling contribute to GBM progression, therapeutic resistance, and treatment-related neurotoxicity. Therefore, this review aims to examine the complex interplay among antioxidants, BDNF/TrkB signaling, and redox imbalance in GBM, focusing on the potential biological activities of natural antioxidants, particularly polyphenols such as curcumin, resveratrol, and epigallocatechin-3-gallate (EGCG). Preclinical studies suggest that these compounds may modulate oxidative stress, influence glioma cell survival, and alter signaling pathways associated with chemoradiotherapy sensitivity and neuronal protection. Nevertheless, direct evidence that BDNF/TrkB signaling mediates the antitumor effects of these antioxidant compounds in glioblastoma remains insufficient, and observations from non-GBM models should be regarded as mechanistic hypotheses rather than validated therapeutic mechanisms. However, clinical evidence supporting their efficacy in patients with GBM remains limited and inconclusive. Human findings from observational cohorts and clinical trials involving non-GBM populations provide indirect insights into antioxidant-related cognitive and redox outcomes but cannot establish therapeutic benefits in glioblastoma. Furthermore, the dual role of BDNF/TrkB signaling in neuronal protection and tumor progression raises concerns regarding generalized BDNF enhancement. Challenges involving bioavailability, optimal dosing, tumor-specific effects, and potential interactions with conventional treatments further limit clinical translation. Future research should prioritize GBM-specific randomized controlled trials, biomarker-guided strategies, and the simultaneous evaluation of neuroprotective and oncological outcomes. Targeting the antioxidant-BDNF-redox axis remains an experimental therapeutic approach that requires rigorous validation before clinical implementation.
Related
- ERK5 Signaling and Ferroptosis in Bone Homeostasis: Emerging Connections and Therapeutic Perspectives
- GSC State Plasticity Drives Therapeutic Resistance and Recurrence in Glioblastoma
- Paired Transcriptomics of Glioblastoma Peripheral and Core Areas Reveals CNTN2 as a Potential Therapeutic Target
- Bee-Derived Products in Neurodegenerative Diseases: Bioactive Constituents, Redox-Modulating Mechanisms, Evidence, and Translational Perspectives
- Novel chemogenetic approaches in modulating calcium signaling
BibTeX
@article{singh2026role,
title = {{Role of Antioxidants in Modulating BDNF Signaling and Oxidative Stress in Glioblastoma: Current Evidence and Therapeutic Perspectives}},
author = {Alka Ashok Singh},
journal = {Cells},
year = {2026},
month = nov,
doi = {10.3390/cells15212006},
url = {https://www.mdpi.com/2073-4409/15/21/2006},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Role of Antioxidants in Modulating BDNF Signaling and Oxidative Stress in Glioblastoma: Current Evidence and Therapeutic Perspectives
AU - Alka Ashok Singh
PY - 2026
DA - 2026/11/04
JO - Cells
DO - 10.3390/cells15212006
UR - https://www.mdpi.com/2073-4409/15/21/2006
AB - Glioblastoma (GBM) remains one of the most aggressive and lethal brain tumors, with limited treatment success despite standard multimodal therapy. Oxidative stress and dysregulated brain-derived neurotrophic factor (BDNF) signaling contribute to GBM progression, therapeutic resistance, and treatment-related neurotoxicity. Therefore, this review aims to examine the complex interplay among antioxidants, BDNF/TrkB signaling, and redox imbalance in GBM, focusing on the potential biological activities of natural antioxidants, particularly polyphenols such as curcumin, resveratrol, and epigallocatechin-3-gallate (EGCG). Preclinical studies suggest that these compounds may modulate oxidative stress, influence glioma cell survival, and alter signaling pathways associated with chemoradiotherapy sensitivity and neuronal protection. Nevertheless, direct evidence that BDNF/TrkB signaling mediates the antitumor effects of these antioxidant compounds in glioblastoma remains insufficient, and observations from non-GBM models should be regarded as mechanistic hypotheses rather than validated therapeutic mechanisms. However, clinical evidence supporting their efficacy in patients with GBM remains limited and inconclusive. Human findings from observational cohorts and clinical trials involving non-GBM populations provide indirect insights into antioxidant-related cognitive and redox outcomes but cannot establish therapeutic benefits in glioblastoma. Furthermore, the dual role of BDNF/TrkB signaling in neuronal protection and tumor progression raises concerns regarding generalized BDNF enhancement. Challenges involving bioavailability, optimal dosing, tumor-specific effects, and potential interactions with conventional treatments further limit clinical translation. Future research should prioritize GBM-specific randomized controlled trials, biomarker-guided strategies, and the simultaneous evaluation of neuroprotective and oncological outcomes. Targeting the antioxidant-BDNF-redox axis remains an experimental therapeutic approach that requires rigorous validation before clinical implementation.
SN - 2073-4409
ER -